Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DISAGREEMENT ON THE STANDARD ADJUVANT TRE ATMENT FOR COLON-CANCER
Autore:
LORENZ M; WALDEYER M; ENCKE A;
Indirizzi:
UNIV FRANKFURT,KLIN ALLGEMEINCHIRURG,THEODOR STERN KAI 7 D-60590 FRANKFURT GERMANY
Titolo Testata:
Zentralblatt fur Chirurgie
fascicolo: 4, volume: 122, anno: 1997,
pagine: 210 - 221
SICI:
0044-409X(1997)122:4<210:DOTSAT>2.0.ZU;2-O
Fonte:
ISI
Lingua:
GER
Soggetto:
RANDOMIZED CONTROLLED TRIAL; COLORECTAL-CANCER; INTRAPERITONEAL 5-FLUOROURACIL; LARGE-BOWEL; FOLLOW-UP; THERAPY; CARCINOMA; FLUOROURACIL; LEVAMISOLE; ADENOCARCINOMA;
Keywords:
COLON CANCER; ADJUVANT SYSTEMIC THERAPY; ADJUVANT REGIONAL THERAPY; ADJUVANT IMMUNOTHERAPY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
58
Recensione:
Indirizzi per estratti:
Citazione:
M. Lorenz et al., "DISAGREEMENT ON THE STANDARD ADJUVANT TRE ATMENT FOR COLON-CANCER", Zentralblatt fur Chirurgie, 122(4), 1997, pp. 210-221

Abstract

Since 5-fluorouracil (5-FU) plus levamisole substantially reduces therecurrence rate and improves survival in adjuvantly treated patients with curative resected stage III colon cancer this combination has been considered the standard therapy. Shortly thereafter folinic acid modulated 5-FU-therapy also demonstrated adjuvant efficacy compared to surgery alone. Therefore various schedules of folinic acid modulated 5-FU-therapg were compared with the standard regimen (5-FU/levamisole). Randomized multicentric studies revealed: In three of four studies 5-FU/FA is superior to 5-FU/levamisole. Treatment duration of 6 months for5-FU/FA is similar to 12 months 5-FU/Levamisole. No benefit is obtained for 5-FU/FA by additional levamisole. The effect of regional (portal vein or intraperitoneal) treatment is controversial discussed, but combination of the treatment with systemic chemotherapy versus 5-FU/levamisole demonstrated slightly increased therapeutic efficacy. Immunotherapy with autologous tumor cell-BCG or monoclonal antibody treatment improved survival and is currently investigated in studies with conventional systemic treatment and combined chemoimmunotherapy. Beside treatment in studies patients with colon cancer stage III should be offered adjuvant chemotherapy with 5-FU/FA. Further improvements and adjuvant treatment protocols for stage II carcinoma have to be investigated in studies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:23:40